Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Hugel Inc (145020 KS): Record High 1Q Earnings; Global Expansion to Accelerate Growth Ahead

Hugel (145020) Vs Medy Tox: Market Neutral Trade

Hugel Inc (145020 KS): Strong Overseas Sales Drive 2Q Performance; Positive Outlook

Hugel Inc (145020 KS): Disappointing Domestic Sales Dragged 3Q Performance; Export Remains Strong

Hugel Inc (145020 KS): Record High 1Q Earnings; US Commercialization and UAE Debut to Trigger Growth

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hugel-inc" target="_blank" data-smartkarma-citation="entities:22860:1" rel="noopener">Hugel Inc (145020 KS)</a> reported 2025 results with revenue of KRW425B, operating profit of KRW202B, and net profit of KRW144B. The results represent the highest in the company’s history.</li>
<li>This year, Hugel will pursue "hybrid sales" strategy, combining distribution through existing partners with direct sales in the U.S., which should improve profitability, driving stable sales, and market share expansion.</li>
<li>Hugel has set a target of KRW900B revenue by 2028 (2025–2028 CAGR: 28%), with US sales accounting for 30% of total sales and maintaining industry leading operating profit margin.</li>
</ul>



Hugel Inc (145020 KS) reported 2025 results with revenue of KRW425B, operating profit of KRW202B, and net profit of KRW144B. The results represent the highest in the company’s history.
This year, Hugel will pursue "hybrid sales" strategy, combining distribution through existing partners with direct sales in the U.S., which should improve profitability, driving stable sales, and market share expansion.
Hugel has set a target of KRW900B revenue by 2028 (2025–2028 CAGR: 28%), with US sales accounting for 30% of total sales and maintaining industry leading operating profit margin.


Hugel Inc (145020 KS): Record High Result for 2025; Eyes U.S.-Led Growth Strategy Ahead